Monopar Therapeutics Inc.
$69.00-$1.29 (-1.8%)
Last close · Data as of Nov 20, 2026
- Market cap
- $399.3M
- P/E
- -29.1x
- EV / EBITDA
- -20.2x
- Revenue
- $0.00
- ROCE
- -12.1%
Price chart
Technical chartScreen technicals →-16.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -7.0%
- 3M
- -37.8%
- 6M
- +6.2%
- 1Y
- -16.9%
- 5Y
- Hidden
- This period includes a one-day price step on 24 Oct 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$1.29 (-1.8%) from $70 to $69 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MNPR, bought on each weekday since 2021.
News & filings
What Monopar Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 13.7 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are more than ten times current liabilities.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Read moreShow less
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
- Sector
- Healthcare
- Shares outstanding
- 6.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $399.3M
- P/E
- -29.1x
- P/B
- 2.9x
- EV / EBITDA
- -20.2x
- 52-week high
- $123.84
- 52-week low
- $50.12
Profitability
- ROE
- -10.0%
- ROCE
- -12.1%
- ROIC
- -17.3%
- ROA
- -9.7%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -12.0%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$12.2M
Solvency
- Current ratio
- 51.35
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 0.89
- Cash / Market cap
- 15.5%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$10.5M |
| FY2023 | $0.00 | -$8.4M |
| FY2024 | $0.00 | -$15.6M |
| FY2025 | $0.00 | -$13.7M |
Cash flows
FY2025: -$12.2M from operations, -$12.2M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$7.2M | -$7.2M |
| FY2023 | -$7.9M | -$7.9M |
| FY2024 | -$6.4M | -$6.4M |
| FY2025 | -$12.2M | -$12.2M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$16.7M
- Net profit
- -$13.7M
- Cash from operations
- -$12.2M
- Free cash flow
- -$12.2M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$16.7M | -$13.7M | -$12.2M | -10.0% | — | -12.0% |
Monthly returns
Month-by-month returns of MNPR across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $140.7M |
| Current assets | $140.5M |
| Non-current assets | $250.0k |
| Liabilities | $2.9M |
| Current liabilities | $2.7M |
| Non-current liabilities | $150.0k |
| Equity | $137.8M |
| Paid-in capital | $227.2M |
| Retained earnings | -$89.5M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; MNPR highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Monopar Therapeutics Inc., Compass Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc.MNPRthis company | $399.3M | -29.1x | 2.9x | -10.0% | -20.2x |
| Orthofix Medical Inc.OFIX | $418.0M | -4.5x | 0.9x | -20.5% | 51.8x |
| Cross Country Healthcare, Inc.CCRN | $409.0M | -4.3x | 1.3x | -29.4% | -4.7x |
| Upstream Bio, Inc.UPB | $404.3M | -2.8x | 1.2x | -42.2% | -1.9x |
| AirSculpt Technologies, Inc.AIRS | $402.8M | -34.5x | 4.6x | -13.3% | 391.4x |
| Community Health Systems, Inc.CYH | $393.2M | 0.8x | -0.3x | -36.5% | 5.5x |
| TruBridge, Inc.TBRG | $390.7M | 89.7x | 2.2x | 2.4% | 12.5x |
| OmniAb, Inc.OABI | $385.6M | -6.0x | 1.4x | -24.3% | -8.1x |
| Compass Therapeutics, Inc.CMPX | $383.6M | -5.8x | 1.9x | -33.8% | -5.1x |
| Peer median | — | -4.4x | 1.4x | -26.8% | 1.8x |
Year-to-date ROI
MNPR since 1 January, against earlier years.
Historical volatility
MNPR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $16.7M |
| Research and developmentResearch And Development | $9.9M |
| Selling, general and administrativeSelling General And Administration | $6.8M |
| Total expensesTotal Expenses | $16.7M |
| Operating incomeOperating Income | -$16.7M |
| Interest and other | |
| Pretax incomePretax Income | -$13.7M |
| Tax | |
| Net incomeNet Income | -$13.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $140.7M |
| Current assetsCurrent Assets | $140.5M |
| Non-current assetsTotal Non Current Assets | $250.0k |
| LiabilitiesTotal Liabilities Net Minority Interest | $2.9M |
| Current liabilitiesCurrent Liabilities | $2.7M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $150.0k |
| EquityTotal Equity Gross Minority Interest | $137.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$12.2M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$12.2M |
| Net income, continuing operationsNet Income From Continuing Operations | -$13.7M |
| Amortization of securitiesAmortization Of Securities | -$720.0k |
| Stock-based compensationStock Based Compensation | $4.8M |
| Change in working capitalChange In Working Capital | -$2.6M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | -$63.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$63.5M |
| Purchase of investmentsPurchase Of Investment | -$87.2M |
| Sale of investmentsSale Of Investment | $23.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$63.5M |
| Financing cash flowFinancing Cash Flow | $91.6M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $91.6M |
| Debt issuedIssuance Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | — |
| Long-term debt issuedLong Term Debt Issuance | — |
| Net long-term debt issuedNet Long Term Debt Issuance | — |
| Shares issuedIssuance Of Capital Stock | $127.1M |
| Common stock issuedCommon Stock Issuance | $127.1M |
| Net common stock issuedNet Common Stock Issuance | $92.1M |
| Common stock repurchasedCommon Stock Payments | -$35.0M |
| Share buybacksRepurchase Of Capital Stock | -$35.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $570.0k |
| Other financing chargesNet Other Financing Charges | -$1.1M |
| Change in cashChanges In Cash | $15.9M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 10.0% |
| Cash at the start of the yearBeginning Cash Position | $45.8M |
| Cash at the end of the yearEnd Cash Position | $61.8M |
| Free cash flowFree Cash Flow | -$12.2M |
Learn while you research
Academy chapters picked for Monopar Therapeutics Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read